Protagenic Therapeutics, Inc. PTIX 深 滬
已收盤 09-05 16:00:00 美东时间
3.15
+0.050
+1.61%
華盛通- 最 高3.21
- 今 開3.10
- 成交量 12.96万股
- 最 低 3.095
- 昨 收 3.10
- 總市值 273.55万
- 52周最高 15.26
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 2.25
- 委 比 46.20%
- 總股本 86.84万
- 歷史最高 273.84
- 量 比 0.87
- 振 幅 3.71%
- 歷史最低 2.506
- 每 手 1
- 風險率 2.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ModivCare (NASDAQ:MODV) stock increased by 69.6% to $0.95 during Frida...
08-22 20:08
Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress
Shares of Protagenic Therapeutics are trading sharply higher Thursday afternoon. The stock soared over 100% midday after the company announced a key clinical milestone.
08-22 03:32
Protagenic Completes First Dose Injections In Phase I Multiple-Dose Study Of PT00114; Topline Safety Data Expected By September; Phase 2 Launch Targeted For Q1 2026
Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical company
08-21 20:16
Protagenic Therapeutics Restructures to Focus on PT00114
Protagenic Therapeutics ( ($PTIX) ) just unveiled an announcement. On August 8,...
08-14 05:58
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics received a patent (JP 7714571B) in Japan for a modified stilbenoid to treat epilepsy and seizures. The patent, granted on July 18, 2025, provides exclusivity until March 2041. Colin Stott highlighted the importance of this patent, following its previous grant in the UK, and plans to expand its coverage in other territories. Japan's pharmaceutical market is the world's third largest, valued at over $85 billion in 2025 and e...
07-30 12:30
Protagenic Therapeutics Appoints Timothy Wright to Board
The latest update is out from Protagenic Therapeutics ( ($PTIX) ). On July 18, ...
07-25 00:58
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities
Predictive Oncology Inc. announced a $10 million securities purchase agreement with Yorkville Advisors Global to support expansion of its ChemoFx assay in the U.S. and Europe. ChemoFx, a live-cell tumor profiling assay, helps oncologists make personalized treatment decisions. The company also advances AI-driven drug discovery and biomarker efforts using its biobank of 150,000 tumor samples. Discussions with potential partners are underway to expa...
07-15 13:00
Protagenic Therapeutics Announces Share Purchase Rights Distribution
Protagenic Therapeutics ( ($PTIX) ) has provided an announcement. On June 24, 2...
06-28 05:53
Protagenic Therapeutics Issues Common Stock for Warrants
The latest announcement is out from Protagenic Therapeutics ( ($PTIX) ). Protag...
05-21 00:18
